In a November 2023 Investor Presentation LC stated that part of Imugene’s commercial strategy is for BP to buy out various products that have proven themselves in clinical trials. So, by that definition would we receive a dividend? If so, then prior to this, our share price should fluctuate in terms of likelihood of OnCarlytics, MAST etc. reaching a level of risk/reward that makes a particular BP or, better still, multiple BP’s partake in a bidding war.
Today’s presentation should tighten the sphincters of shorters, and very soon I would be expecting some covering. Perhaps at the bottom of the gap that charters are identifying?
In a November 2023 Investor Presentation LC stated that part of...
-
- There are more pages in this discussion • 1,280 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $409.9M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.6¢ | $323.5K | 5.744M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 1281090 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1026096 | 25 |
View Market Depth
| Last trade - 13.25pm 19/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |